Following the political and social upheaval of the Arab Spring, Hikma Pharmaceuticals is poised for expansion into markets that are now much more receptive than before. Said Darwazah, CEO of the Jordan-based speciality pharma group, told Scrip that while the political disruptions in the Middle East only cut a company-estimated $20 million from sales revenue in 2011, the situation has transformed some markets into an opportunity for accelerated growth.
"Governments are responding to the Arab Spring by increasing spending on healthcare," observed Mr Darwazah, adding that Hikma was well...